Search

News How and How the Czech National Hemophilia Program Benefits Professionals and Patients

The Czech National Hemophilia Program (ČNHP) has been an interdisciplinary initiative for many years, coordinating specialized care for both pediatric and adult patients with hemophilia and other congenital bleeding disorders in the Czech Republic. It was established on the platform of collaboration among experts from hematology centers that deal with this issue and is guided by the ČNHP Declaration, which is published on the association's website (see www.cnhp.cz).

Source: Von Willebrand Disease 25. 2. 2022

News Ixekizumab is a Safe Option for Long-Term Treatment of Inflammatory Diseases

Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (SpA) are chronic inflammatory diseases that often require long-term treatment. The current pharmacotherapy of these diseases includes conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and targeted biological therapies that inhibit the effects of tumor necrosis factor (TNF) or interleukins IL-23 and IL-17. An analysis published in early 2020 in the journal Rheumatology focused on the safety of long-term inhibition of IL-17A using ixekizumab.

Source: Biological Treatment 26. 10. 2020

Články časopisu How prevalent is being born small for gestational age? Analysis of 7341 children from the ELSPAC study population

Author of the article: D. Novotná, P. Okrajek, Z. Doležel, L. Kukla, J. Lebl Source: Česko-slovenská pediatrie | 2/2011 25. 2. 2011

News Teriflunomide vs. Dimethyl Fumarate: Does Their Classification into Different Treatment Lines Have Merit?

Teriflunomide is one of the first-choice medications in the treatment of multiple sclerosis (MS) patients, not only in the Czech Republic. Conversely, the use of dimethyl fumarate is more limited here compared to other countries. Did the data from real-world clinical practice published this year actually demonstrate differences in the efficacy of both medications, and thus justify their classification?

Source: Multiple Sclerosis 4. 1. 2023

News Teriflunomide vs. Dimethyl Fumarate in Real Practice: We Know the Winner! Will It Surprise You?

Teriflunomide and dimethyl fumarate are disease-modifying drugs (DMDs) used in the treatment of multiple sclerosis (MS). Regarding the course, form, and severity of MS, their target groups are comparable in their characteristics. These DMDs are therefore ideal candidates for mutual comparison. Swedish authors decided to compare their effectiveness based on data from real clinical practice obtained through the Swedish National Registry.

Source: Multiple Sclerosis 31. 7. 2021

News Algorithm for Choosing Antidiabetics in Patients with Type 2 Diabetes

As of June 1, 2020, general practitioners can prescribe antidiabetics from the group of so-called gliptins, inhibitors of the enzyme dipeptidyl peptidase 4 (DPP-4i), in addition to metformin. The cornerstone of type 2 diabetes mellitus treatment remains a comprehensive lifestyle modification (dietary measures, increased physical activity, weight reduction) and metformin as the first-line drug. In selected comorbidities or if these measures do not lead to the desired glycated hemoglobin (HbA1c) level after 3-6 months, the following recommendations can be followed. However, it is essential to remember that the recommendations of professional societies do not always correspond to the prescription limitations of the State Institute for Drug Control (SÚKL).

Source: Diabetes 29. 7. 2020

News Nearly 20 Years with Bevacizumab Has Brought Hope for Patients and Deeper Understanding of Solid Tumors

Bevacizumab is among the first targeted therapies used in oncology. For many indications where chemotherapy options had been exhausted and few other treatment modalities were available, it changed the treatment approach and brought patients prolonged progression-free survival or even overall survival. It has become a standard of care for many advanced cancers. What do we know today about this monoclonal antibody, first introduced in routine practice in 2005?

Source: Oncological Treatment 19. 8. 2022

News Experiences with the Treatment of Coagulopathy in Obstetrics –⁠ ROTEM-Guided Algorithm

An observational study from a hospital in Liverpool, UK, was published in the journal Anaesthesia, where they implemented a bleeding management algorithm for obstetric procedures based on rotational thromboelastometry (ROTEM) testing. After 4 years of using this algorithm, it was found that selective administration of fibrinogen concentrates based on ROTEM results led to better clinical outcomes in the treatment of coagulopathy.

Source: Life-threatening Bleeding 7. 7. 2022

News Subclinical Hypothyroidism Associated with the Use of Allopurinol? What the Results of a Large Multicenter Study Suggested

Allopurinol is a widely used drug for the treatment of hyperuricemia and gout. The retrospective study presented below investigated whether its long-term use is associated with an increased risk of developing subclinical hypothyroidism.

Source: Thyroid Disorders 18. 11. 2021

News Targeted Treatment of Metastatic Breast Cancer in the 2nd Line –⁠ Experiences from Practice

The recommended treatment for metastatic HER2-positive breast cancer in the 1st line involves dual blockade of the HER2 signaling pathway using trastuzumab and pertuzumab in combination with a taxane cytostatic. After the failure of this therapy, treatment with trastuzumab emtansine (T-DM1) is recommended. However, this recommendation is not supported by a prospectively designed controlled study examining the outcomes of this therapeutic sequence. Therefore, a group of Italian authors decided to publish the results of a patient cohort treated with this sequence in real clinical practice conditions.

Source: Breast Carcinoma 23. 11. 2020

News Detection of von Willebrand Disease

Von Willebrand disease (vWD) is an autosomal hereditary bleeding disorder. Its detection and diagnosis require several steps, including the initial suspicion of the presence of this disease.

Source: Von Willebrand Disease 23. 3. 2021

News INFOGRAPHIC: Eye Drops for Dry and Irritated Eyes –⁠ Mechanism of Action and Benefits

Source: Ophthalmologic Diseases 2. 5. 2023

News How Do Patients Themselves Perceive Today's Treatment Options for ITP and What Are Their Biggest Fears?

What is the perception and view of the treatment options for immune thrombocytopenia (ITP) from the patients' perspective, what do they fear, what approaches do they prefer, and why? Lozano et al. included a discussion on this topic in their review article for Expert Review of Hematology, which can be helpful in clinical practice for better understanding patients' needs and adjusting treatment algorithms.

Source: Immune Thrombocytopenia 21. 11. 2023

News Proton Therapy and Its Results in the Treatment of Bilateral Breast Cancer

Breast cancer is the most common malignant tumor disease in women, and its incidence sharply increases after the age of 50. Although its incidence shows a continuously increasing trend, the development of mortality is more favorable. Thanks to nationwide screening and more successful therapy, mortality has long been stable, even slightly decreasing. A relatively rare variant of this oncological disease is primary synchronously detected bilateral breast cancer (PSBBC). Experts from the Proton Therapy Center in Prague are focusing on the use of proton radiotherapy in the treatment of this clinical entity.

Source: Proton Radiotherapy 11. 5. 2023

News What Can We Expect from Sorafenib in the Treatment of Liver Cancer Affected by Nonalcoholic Fatty Liver Disease?

Ubiquitous and increasingly common obesity is a risk factor for many cancers. Over the past 20 years, studies have linked obesity to higher incidences of breast and colorectal cancers, as well as hepatocellular carcinoma (HCC) associated with nonalcoholic fatty liver disease (NAFLD). What is the efficacy and safety of sorafenib in this patient population, and does it differ from patients with liver cancers caused by viral infection or alcohol abuse? This intrigued a team of researchers from Melbourne, Australia.

Source: Oncological Treatment 31. 10. 2022